IF THERE Was Ever Any Doubt That the Humble Vaccine, for Years a Backwater of Pharmaceutical Research, Is Back in Fashion Then the Rising Fortunes of Powderject Pharmaceuticals and Acambis Have Put Paid to That

Sunday Business (London, England), August 18, 2002 | Go to article overview

IF THERE Was Ever Any Doubt That the Humble Vaccine, for Years a Backwater of Pharmaceutical Research, Is Back in Fashion Then the Rising Fortunes of Powderject Pharmaceuticals and Acambis Have Put Paid to That


IF THERE was ever any doubt that the humble vaccine, for years a backwater of pharmaceutical research, is back in fashion then the rising fortunes of Powderject Pharmaceuticals and Acambis have put paid to that.

Over the past few months, Britains two vaccine specialists have been as much in the news for their stellar share price performances as for their rivalry to secure lucrative government contracts.

Both have seen their shares soar and their balance sheets substantially bolstered by winning government contracts to supply a smallpox vaccine, Powderject for the UK, Acambis for the US.

The ongoing controversy surrounding the award of the ? (E36.8m) British government contract to Powderject, whose founder and chief executive Paul Drayson is a British Labour party donor, has given their rivalry an added dimension.

With vaccines such an integral part of governments healthcare policies, especially in the wake of the 11 September terrorist attacks and rising concerns of the threat of biological warfare, both Powderject and Acambis look well placed to continue to benefit from any future commercial developments.

So how do the two rivals match up?

Powderject has changed substantially since it floated in 1997 as a drug delivery company whose key product was its needleless injection system.

A series of acquisitions, notably the vaccines business of Medeva, has turned the company into the sixth-largest vaccines maker in the world. Aside from vaccines for flu, tuberculosis and smallpox, Powderject is also involved in research into groundbreaking new products such as a DNA vaccine to prevent hepatitis B infection.

The companys flu vaccine makes up the bulk of its profits and a 45% sales jump of the vaccine helped Powderject report a pre-tax profit of ?,000, (E160,000) compared with a loss of ?5m (E32.8m) in the year to March 2001.

Much of the euphoria, however, was wiped out last week after Powderject was forced to issue a profit warning on the back of recalling its tuberculosis vaccines in the UK after worries over adequate potency levels.

The recall is also likely to lead to a pre-tax profit shortfall of ?(E8m) for the fiscal year of 2003 and industry sources believe Powderject may not win the contract when it comes up again for tender at the end of the year.

Unfortunately for Powderject, last weeks product recall is just the latest blow to the company which has been dogged by controversy ever since it emerged that Drayson donated ? …

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

IF THERE Was Ever Any Doubt That the Humble Vaccine, for Years a Backwater of Pharmaceutical Research, Is Back in Fashion Then the Rising Fortunes of Powderject Pharmaceuticals and Acambis Have Put Paid to That
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.